JP2023514659A5 - - Google Patents

Info

Publication number
JP2023514659A5
JP2023514659A5 JP2022537837A JP2022537837A JP2023514659A5 JP 2023514659 A5 JP2023514659 A5 JP 2023514659A5 JP 2022537837 A JP2022537837 A JP 2022537837A JP 2022537837 A JP2022537837 A JP 2022537837A JP 2023514659 A5 JP2023514659 A5 JP 2023514659A5
Authority
JP
Japan
Prior art keywords
polypeptide
amino acid
seq
interferon
homology
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022537837A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023514659A (ja
JP7786010B2 (ja
Filing date
Publication date
Priority claimed from ARP190103715A external-priority patent/AR117715A1/es
Application filed filed Critical
Publication of JP2023514659A publication Critical patent/JP2023514659A/ja
Publication of JP2023514659A5 publication Critical patent/JP2023514659A5/ja
Application granted granted Critical
Publication of JP7786010B2 publication Critical patent/JP7786010B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022537837A 2019-12-17 2020-12-16 免疫原性が低下した修飾インターフェロン－アルファ－２ Active JP7786010B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AR20190103715 2019-12-17
ARP190103715A AR117715A1 (es) 2019-12-17 2019-12-17 Interferón hiperglicosilado con inmunogenicidad reducida
PCT/US2020/065246 WO2021126929A1 (en) 2019-12-17 2020-12-16 Modified interferon-alpha-2 having reduced immunogenicity

Publications (3)

Publication Number Publication Date
JP2023514659A JP2023514659A (ja) 2023-04-07
JP2023514659A5 true JP2023514659A5 (https=) 2023-12-25
JP7786010B2 JP7786010B2 (ja) 2025-12-16

Family

ID=76478524

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022537837A Active JP7786010B2 (ja) 2019-12-17 2020-12-16 免疫原性が低下した修飾インターフェロン－アルファ－２

Country Status (7)

Country Link
US (1) US20230127506A1 (https=)
EP (1) EP4076504A4 (https=)
JP (1) JP7786010B2 (https=)
AR (1) AR117715A1 (https=)
BR (1) BR112022011975A2 (https=)
MX (1) MX2022007546A (https=)
WO (1) WO2021126929A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240067691A1 (en) 2022-08-18 2024-02-29 Regeneron Pharmaceuticals, Inc. Interferon receptor agonists and uses thereof
CN120051483A (zh) 2022-08-18 2025-05-27 再生元制药公司 干扰素前蛋白及其用途
CN121752592A (zh) 2023-05-12 2026-03-27 再生元制药公司 干扰素受体拮抗剂及其用途
CN116814595B (zh) * 2023-08-30 2023-11-28 江苏申基生物科技有限公司 一种腺苷脱氨酶突变体及其固定化

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US20060062761A1 (en) * 2001-03-02 2006-03-23 Carr Francis J Modified interferon alpha with reduced immunogenicity
WO2006020580A2 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
AU2006255122B2 (en) 2005-06-03 2010-10-21 Ambrx, Inc. Improved human interferon molecules and their uses
AU2006263331B2 (en) 2005-06-29 2012-02-16 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Recombinant interferon alpha2 (IFNalpha2) mutants
AR057215A1 (es) 2006-12-01 2007-11-21 Univ Nac Del Litoral Unl Proteina de fusion
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
CA2695543A1 (en) 2007-08-06 2009-02-12 Schering Corporation Gamma secretase modulators
US10544199B2 (en) 2014-10-29 2020-01-28 Teva Pharmaceuticals Australia Pty Ltd Interferon alpha 2B variants
AR102120A1 (es) 2015-09-29 2017-02-08 Univ Nac Del Litoral Interferón modificado con inmunogenicidad reducida
WO2019147837A2 (en) 2018-01-24 2019-08-01 Beijing Percans Oncology Co. Ltd. Cytokine fusion proteins

Similar Documents

Publication Publication Date Title
JP2023514659A5 (https=)
US12152060B2 (en) Interleukin-2 variants and methods of uses thereof
TWI648401B (zh) 生長分化因子１５（ｇｄｆ－１５）構築體
JP2022115876A5 (https=)
JP2024178382A5 (https=)
JP2004536077A5 (https=)
JP2021512126A5 (https=)
CA2529179A1 (en) Recombinant adeno-associated virus vector for treatment of alzheimer disease
JP7702445B2 (ja) 免疫調節融合タンパク質
JP2016519569A5 (https=)
RU2012107671A (ru) Композиция для лечения инфекции вирусом гепатита в
CN111954537A (zh) 生长分化因子15融合蛋白
DE69805844T2 (de) Ifnnar/ifn komplex
JP2007535910A5 (https=)
CN111499718A (zh) 人α干扰素受体结合相关位点突变体及其用途
EP1622939A1 (en) Active variants of the il-18 binding protein and medical uses thereof
JP2024525213A5 (https=)
RU2010141916A (ru) Растворимый мутант рецептора фактора некроза опухоли
JP5209462B2 (ja) コンセンサスインターフェロンの使用方法
JP2022169770A (ja) タンパク質の半減期を増加させる方法
US7642072B2 (en) Optimized interferon-beta gene
JP2023522423A (ja) インターフェロンアルファ２バリアント及びその使用
WO2003059950A1 (en) Ifnar2 mutants, their production and use
Garotta et al. Development of interferon-γ antagonists as an example of biotechnology application to approach new immunomodulators
WO2021233094A1 (zh) 干扰素-κ突变体及其制备方法